https://assets.capyfin.com/instruments/678fdc13234e27009c5d57fc.png avatar
McKesson
🇺🇸 NYSE:MCK
View Company
OverviewEarningsDividends
•
Sep 30, 2023

McKesson Q2 2024 Earnings Report

McKesson's second quarter performance exceeded expectations, demonstrating progress against company priorities, driven by the dedication of McKesson team members and strength in oncology and biopharma services platforms, leading to raised full-year guidance.

Key Takeaways

McKesson Corporation reported a 10% increase in total revenues to $77.2 billion for the second quarter of fiscal year 2024. Earnings per diluted share decreased by $1.54 to $4.92, while adjusted earnings per diluted share increased by 3% to $6.23. The company raised its full-year adjusted earnings per diluted share guidance to a range of $26.80 to $27.40.

Total revenues increased by 10% to $77.2 billion.

Earnings per diluted share decreased to $4.92.

Adjusted Earnings per Diluted Share increased 3% to $6.23.

Fiscal 2024 Adjusted Earnings per Diluted Share guidance range increased to $26.80 to $27.40.

Total Revenue
$77.2B
Previous year: $70.2B
+10.1%
EPS
$6.23
Previous year: $6.06
+2.8%
Gross Profit
$3.07B
Previous year: $3.1B
-0.8%
Cash and Equivalents
$2.52B
Previous year: $2.92B
-13.4%
Free Cash Flow
-$351M
Previous year: -$56M
+526.8%
Total Assets
$66.1B
Previous year: $63.1B
+4.8%

McKesson

McKesson

McKesson Revenue by Segment

Forward Guidance

McKesson is raising fiscal 2024 Adjusted Earnings per Diluted Share guidance to $26.80 to $27.40 from the previous range of $26.55 to $27.35 to reflect solid operating business performance.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View McKesson